论文部分内容阅读
目的观察瑞舒伐他汀预防初诊肥胖型2型糖尿病的大血管并发症的临床效果。方法将212例初诊肥胖型2型糖尿病患者随机分为治疗组和对照组各106例。对照组采用盐酸二甲双胍治疗。治疗组在对照组基础上加用瑞舒伐他汀睡前服用。治疗后随访2组大血管并发症发生率。结果治疗组不稳定心绞痛、急性心肌梗死、脑血管意外、外周血管病变等糖尿病大血管并发症发生率和病死率均低于对照组,差异均有统计学意义(P<0.05)。结论瑞舒伐他汀的应用可明显预防初诊肥胖型2型糖尿病患者大血管并发症发生率,改善了患者预后,提高了患者的生活质量,值得临床推广应用。
Objective To observe the clinical effect of rosuvastatin in preventing macrovascular complications of newly diagnosed obese type 2 diabetes mellitus. Methods 212 newly diagnosed obese type 2 diabetic patients were randomly divided into treatment group and control group of 106 cases. The control group was treated with metformin hydrochloride. The treatment group was given rosuvastatin on the basis of the control group before bedtime. After treatment, the incidence of macrovascular complications in two groups were followed up. Results The incidence and mortality of macrovascular complications such as unstable angina pectoris, acute myocardial infarction, cerebrovascular accident and peripheral vascular disease in the treatment group were significantly lower than those in the control group (P <0.05). Conclusion The application of rosuvastatin can significantly prevent the incidence of major vascular complications in newly diagnosed obese type 2 diabetic patients, improve the prognosis of patients and improve the quality of life of patients, worthy of clinical application.